Research information only, not medical advice. Semaglutide is titrated gradually from a low starting dose. For weight management (Wegovy) the maintenance dose is 2.4 mg once weekly by subcutaneous injection; for type 2 diabetes (Ozempic) it is dosed lower, and an oral form (Rybelsus) is a daily tablet. These are the approved schedules, not medical advice.
Semaglutide is FDA-approved as Ozempic (type 2 diabetes), Wegovy (weight management) and the oral tablet Rybelsus. The injectable forms start at a low dose and are titrated up over several weeks — the maintenance dose for weight management is 2.4 mg once weekly — because gastrointestinal effects are greatest early in titration. This page reports the approved schedules, not a protocol to follow.
For the full evidence base, clinical trials, and regulatory status, see the Semaglutide research overview . Related: semaglutide side effects , semaglutide before and after .
Sources
Frequently asked questions
- What is the maintenance dose of semaglutide for weight loss?
- For weight management (Wegovy), 2.4 mg once weekly by subcutaneous injection, reached by gradual titration from a lower starting dose.
- Is there an oral form of semaglutide?
- Yes — Rybelsus is an oral semaglutide tablet taken once daily, approved for type 2 diabetes. This is label information, not medical advice.
Updated · sourced to primary documents